NEUROCRINE BIOSCIENCES INC Number of Reportable Segments
NEUROCRINE BIOSCIENCES INC (NBIX) reported Number of Reportable Segments of 1 segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-07-31
- NEUROCRINE BIOSCIENCES INC number of reportable segments for the quarter ending 2026-03-31 was 1.00 segment.
- NEUROCRINE BIOSCIENCES INC number of reportable segments for fiscal 2025 was 1.00 segment, a 0.00% change from fiscal 2024.
- NEUROCRINE BIOSCIENCES INC number of reportable segments for fiscal 2024 was 1.00 segment, a 0.00% change from fiscal 2023.
- NEUROCRINE BIOSCIENCES INC number of reportable segments for fiscal 2023 was 1.00 segment, a 0.00% change from fiscal 2022.
- NEUROCRINE BIOSCIENCES INC number of reportable segments for fiscal 2022 was 1.00 segment, a 0.00% change from fiscal 2021.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 12 month |
|---|---|---|---|
| 2026-06-30 | 1.00 segment 10-Q · filed 2026-07-31 | ||
| 2026-03-31 | 1.00 segment 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | 1.00 segment 10-K · filed 2026-02-11 | ||
| 2024-12-31 | 1.00 segment 10-K · filed 2025-02-10 | ||
| 2023-12-31 | 1.00 segment 10-K · filed 2024-02-09 | ||
| 2022-12-31 | 1.00 segment 10-K · filed 2023-02-09 | ||
| 2021-12-31 | 1.00 segment 10-K · filed 2022-02-11 | ||
| 2020-12-31 | 1.00 segment 10-K · filed 2021-02-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |